Canarys has announced the launch of Auryis, an AI-driven, unified compliance assessment platform tailored for the Pharma and Life Sciences sector. The launch signals Canarys’ strategic transition from a services-led to a product-led company.
In today’s rapidly evolving regulatory environment, Auryis provides real-time, structured, and audit-ready compliance insights across diverse digital content—ranging from SOPs and clinical trial documents to training materials and marketing assets. The platform automatically maps each content element to external regulations (GxP, FDA, EMA), internal standards, and business-specific rules, enabling organizations to proactively manage compliance risks.
Seamless content assessment: Analyzes varied formats, linking them to regulatory requirements.
Automated risk detection: Flags compliance gaps instantly and prioritizes high-impact issues.
Human-in-the-loop intelligence: Empowers SME review and feedback to refine AI accuracy.
Custom rule integration: Adapts quickly to new policies, trial conditions, and regulatory updates.
Continuous learning: Keeps pace with global regulations while reducing manual workloads.
Sheshadri Srinivas, CEO of Canarys, stated:
“Pharma and Life Sciences companies face mounting compliance pressures that delay approvals and impact patient safety. With Auryis, compliance becomes smarter, faster, and continuous—delivering audit-ready insights, minimizing risks, and driving operational excellence. This launch marks a defining milestone in our journey to becoming a product-led organization.”
Reduced training effort via guided reviews
Lower costs and faster compliance cycles
Early risk identification and mitigation
Continuous compliance improvement at scale
Auryis—where AI accelerates compliance and human expertise elevates trust.